Purpose To assess whether indomethacin eye drops and intravitreal ranibizumab (IVR) would provide additional benefit over IVR alone in the treatment of naïve choroidal neovascularization (CNV). Methods A total of 22 patients were enrolled consecutively and randomized in a 1:1 ratio to receive combination treatment with monthly IVR and topical indomethacin or monthly IVR alone. Results At 6 months, both groups showed a significant improvement in BCVA. The mean change in central macular thickness (CMT) in the combination group was −129.2 μm (−30.1%; P < .01), while in the ranibizumab-only group, the change was −86.9 mm (−21.1%; P < .01); thus, the combination treatment resulted in a greater reduction (P = .004). Conclusion This pilot study, the first to prospectively investigate the efficacy and safety of a combination of 0.5% indomethacin eye drops and IVR injections in patients with CNV, suggests that topical indomethacin supplements the activity of IVR in reducing CMT in CNV

A randomized controlled trial of ranibizumab with and without indomethacin eyedrops for exudative age-related macular degeneration

RUSSO, Andrea;SEMERARO, Francesco
2016-01-01

Abstract

Purpose To assess whether indomethacin eye drops and intravitreal ranibizumab (IVR) would provide additional benefit over IVR alone in the treatment of naïve choroidal neovascularization (CNV). Methods A total of 22 patients were enrolled consecutively and randomized in a 1:1 ratio to receive combination treatment with monthly IVR and topical indomethacin or monthly IVR alone. Results At 6 months, both groups showed a significant improvement in BCVA. The mean change in central macular thickness (CMT) in the combination group was −129.2 μm (−30.1%; P < .01), while in the ranibizumab-only group, the change was −86.9 mm (−21.1%; P < .01); thus, the combination treatment resulted in a greater reduction (P = .004). Conclusion This pilot study, the first to prospectively investigate the efficacy and safety of a combination of 0.5% indomethacin eye drops and IVR injections in patients with CNV, suggests that topical indomethacin supplements the activity of IVR in reducing CMT in CNV
2016
File in questo prodotto:
File Dimensione Formato  
AAO 2016 poster completo.pdf

gestori archivio

Descrizione: AAO 2016 poster completo e abstract
Tipologia: Abstract
Licenza: DRM non definito
Dimensione 232.29 kB
Formato Adobe PDF
232.29 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11379/484420
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact